Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar

Research output: Contribution to journalArticle

1667 Citations (Scopus)

Abstract

Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods: In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32). Primary efficacy end points were time to disease progression and best confirmed response rate. On disease progression, patients in the control arm had the option to receive single-agent bevacizumab 15 mg/kg every 3 weeks. Results: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47%. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. Conclusion: Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.

Original languageEnglish (US)
Pages (from-to)2184-2191
Number of pages8
JournalJournal of Clinical Oncology
Volume22
Issue number11
DOIs
StatePublished - 2004

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Hemoptysis
Disease Progression
Histology
Hemorrhage
Safety
Survival
Bevacizumab
Reaction Time
Area Under Curve
Blood Vessels
Necrosis
Epithelial Cells
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. / Johnson, David H.; Fehrenbacher, Louis; Novotny, William F.; Herbst, Roy S.; Nemunaitis, John J.; Jablons, David M.; Langer, Corey J.; DeVore, Russell F.; Gaudreault, Jacques; Damico, Lisa A.; Holmgren, Eric; Kabbinavar, Fairooz.

In: Journal of Clinical Oncology, Vol. 22, No. 11, 2004, p. 2184-2191.

Research output: Contribution to journalArticle

Johnson, DH, Fehrenbacher, L, Novotny, WF, Herbst, RS, Nemunaitis, JJ, Jablons, DM, Langer, CJ, DeVore, RF, Gaudreault, J, Damico, LA, Holmgren, E & Kabbinavar, F 2004, 'Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer', Journal of Clinical Oncology, vol. 22, no. 11, pp. 2184-2191. https://doi.org/10.1200/JCO.2004.11.022
Johnson, David H. ; Fehrenbacher, Louis ; Novotny, William F. ; Herbst, Roy S. ; Nemunaitis, John J. ; Jablons, David M. ; Langer, Corey J. ; DeVore, Russell F. ; Gaudreault, Jacques ; Damico, Lisa A. ; Holmgren, Eric ; Kabbinavar, Fairooz. / Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 11. pp. 2184-2191.
@article{df7b5fbf72f84cf2ba12190d861c8e24,
title = "Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer",
abstract = "Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods: In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32). Primary efficacy end points were time to disease progression and best confirmed response rate. On disease progression, patients in the control arm had the option to receive single-agent bevacizumab 15 mg/kg every 3 weeks. Results: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5{\%} v 18.8{\%}), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47{\%}. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. Conclusion: Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.",
author = "Johnson, {David H.} and Louis Fehrenbacher and Novotny, {William F.} and Herbst, {Roy S.} and Nemunaitis, {John J.} and Jablons, {David M.} and Langer, {Corey J.} and DeVore, {Russell F.} and Jacques Gaudreault and Damico, {Lisa A.} and Eric Holmgren and Fairooz Kabbinavar",
year = "2004",
doi = "10.1200/JCO.2004.11.022",
language = "English (US)",
volume = "22",
pages = "2184--2191",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

AU - Johnson, David H.

AU - Fehrenbacher, Louis

AU - Novotny, William F.

AU - Herbst, Roy S.

AU - Nemunaitis, John J.

AU - Jablons, David M.

AU - Langer, Corey J.

AU - DeVore, Russell F.

AU - Gaudreault, Jacques

AU - Damico, Lisa A.

AU - Holmgren, Eric

AU - Kabbinavar, Fairooz

PY - 2004

Y1 - 2004

N2 - Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods: In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32). Primary efficacy end points were time to disease progression and best confirmed response rate. On disease progression, patients in the control arm had the option to receive single-agent bevacizumab 15 mg/kg every 3 weeks. Results: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47%. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. Conclusion: Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.

AB - Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods: In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32). Primary efficacy end points were time to disease progression and best confirmed response rate. On disease progression, patients in the control arm had the option to receive single-agent bevacizumab 15 mg/kg every 3 weeks. Results: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47%. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. Conclusion: Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.

UR - http://www.scopus.com/inward/record.url?scp=2942657615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942657615&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.11.022

DO - 10.1200/JCO.2004.11.022

M3 - Article

C2 - 15169807

AN - SCOPUS:2942657615

VL - 22

SP - 2184

EP - 2191

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -